Skip to main content

Table 2 Multivariable Cox regression analysis of associations between demographic and clinical characteristics and PFS

From: Real-world patient characteristics and treatment outcomes among nontransplanted multiple myeloma patients who received Bortezomib in combination with Lenalidomide and Dexamethasone as first line of therapy in the United States

Characteristic

HR

95% CI

lower limit

95% CI

upper limit

Age at index, years

  < 65

1

–

–

 65 to < 70

0.946

0.750

1.192

 70 to < 75

1.079

0.870

1.338

  ≥ 75

1.370

1.133

1.658

Gender

 Female

0.955

0.825

1.104

 Male

1

–

–

Race

 Black or African American

1.089

0.895

1.326

 Asian or other race

1.069

0.862

1.325

 White

1

–

–

Cytogenetic risk

 High

1.441

1.185

1.751

 Standard

1

–

–

RIa

1.156

0.920

1.453

Diabetes

1.000

0.768

1.301

ISS disease stage

 I

1

–

–

 II

1.310

1.055

1.626

 III

1.370

1.103

1.702

ECOG PS score

 0

1

–

–

 1

1.033

0.862

1.237

  ≥ 2

1.490

1.224

1.814

Year of index date

1.027

0.966

1.092

Time from initial diagnosis to index date, months

1.036

1.015

1.057

  1. PFS progression-free survival, HR hazard ratio, CI confidence interval, RI renal impairment, ICD-9-CM International Classification of Disease, 9th Revision, Clinical Modification; ICD-10-CM International Classification of Disease, 10th Revision, Clinical Modification; ISS International Staging System, ECOG PS Eastern Cooperative Oncology Group performance status
  2. aAcute RI, defined as patients with a serum creatinine > 2 mg/dL on the closest date to the index date or having diagnosis codes of ICD-9-CM 584.5-584.9, ICD-9-CM 586, ICD-10-CM N17.0-2, N17.8-9, and N19, measured ≤90 days prior to and ≤ 7 days after the index date
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us